Cancer Forums and News by PhD's


News | Forums Register

Go Back   Cancer Forums and News by PhD's > Cancer Forums and News

Cancer News

Breast
Colon
Kidney
Leukemia
Liver
Lung
Melanoma
Mesothelioma
Myeloma
Neck
Pancreatic
Prostate


Cancer Review

Breast
Colon
Kidney
Leukemia
Liver
Lung
Melanoma
Mesothelioma
Myeloma
Pancreatic
Prostate


Recent Forum Topics

 
Myeloma
The Combination of Panzem(R) and Velcade(R) in Multiple Myeloma
By admin at 2006-12-13 03:23
 

Panzem(R) is currently being evaluated in Phase 1 and Phase 2 oncology clinical trials, including multiple myeloma. In anticipation of continued clinical trials using Panzem(R) in combination with approved agents, we evaluated the preclinical effectiveness of Panzem(R) alone or with Velcade(R). Part of the rationale for this combination stems from the inhibition of the nuclear transcription factors, NFkappaB and HIF-1alpha, by Velcade(R) and Panzem(R), respectively. Many of Velcade's anti-myeloma effects are believed to be due to the inhibition of proteosome function and blockage of NFkappaB, leading to a downregulation in the expression of various growth, survival, and angiogenic factors.

read more | 1938 reads

Keryx Biopharmaceuticals, Inc. Announces Positive Interim Phase II Data on KRX-0401 (Perifosine) in Patients with Relaps
By admin at 2006-12-12 03:20
 

Keryx Biopharmaceuticals, Inc. (NASDAQ:KERX) today announced that Dr. Paul Richardson, Clinical Director of the Jerome Lipper Multiple Myeloma Center at the Dana-Farber Cancer Institute (DFCI) in Boston, MA reported positive interim results from the phase II study of KRX-0401 in patients with advanced relapsed and refractory multiple myeloma (MM) at the American Society of Hematology (ASH) 48th Annual Meeting and Exposition in Orlando, FL. KRX-0401, the Company's lead oncology compound under development, is a novel, oral, anticancer agent that modulates Akt and several other important signal transduction pathways, including MAP kinase and JNK. KRX-0401 is currently being evaluated in Phase II clinical trials as a single agent and in combination with other anti-cancer agents across several tumor types. Dr. Richardson, along with Dr. Ken Anderson at DFCI and other leading investigators from MM centers including Emory University, University of Michigan, Alta Bates, City of Hope, University of Virginia and Northwestern University have been instrumental in the pre-clinical and clinical development of perifosine for MM. The poster (Abstract # 3582), entitled "A Multicenter Phase II Study of Perifosine (KRX-0401) Alone and in Combination with Dexamethasone (Dex) for Patients with Relapsed or Relapsed/Refractory Multiple Myeloma (MM)," was presented today, December 11th, 2006 at 10:30 am in the Orange County Convention Center. In this ongoing Phase II study, patients with relapsed or relapsed/refractory multiple myeloma are treated with KRX-0401 (150 mg oral daily dose) to assess the single agent activity of KRX-0401 in this patient population. If a patient progresses on KRX-0401 alone, dexamethasone (20mg twice weekly) is added to their KRX-0401 regimen. Results: 55 patients (30 men and 25 women, median age 63 y, range 3879) have been treated to date. All had relapsed and refractory MM, with a median of 4 lines of prior treatment (range 2 - 11). Prior therapy included dex (95%), thalidomide (89%), bortezomib (78%), lenalidomide (31%) and stem cell transplant (73%). Among 33 patients currently evaluable for response, best response (EBMT/Blade criteria) to single agent perifosine after 2 cycles was stable disease (<25% reduction in M-protein) in 13 patients (39%). Dex was added in 30 of 55 patients with PD, with 23 patients evaluable for response on the combination, reported as follows: Perifosine Dex N (%) Duration (wks) PR 2 (9%) 13 , 17 MR 4 (17%) 4, 16 , 28 , 30 Stable Disease 11 (48%) 6 - 20 (median 18)* *4 pts ongoing at 16, 18, 20 and 20 weeks The most common grade 3/4 adverse events were nausea (7%); vomiting (4%); diarrhea (2%); fatigue (2%), and increased creatinine (8% in the context of PD and light chain nephropathy). Dose reduction (150 to 100 or 50 mg/d) was required in 16 patients and 7 patients discontinued treatment due to adverse events. Attributable toxicities otherwise proved manageable with appropriate supportive care. Perifosine was generally well tolerated, with no peripheral neuropathy or DVT seen. The conclusion of the investigators is that Perifosine alone or in combination with dexamethasone has activity in patients with advanced, relapsed/refractory MM, achieving response and/or stabilization of disease in 69% of evaluable patients to date. Commenting on the interim data, Dr. Richardson stated, "We are encouraged by the observed activity of perifosine in combination with dexamethasone in relapsed and refractory patients with multiple myeloma, and the manageable toxicity profile seen to date, with some of our patients remaining on active treatment over 6 months. We look forward to completing enrollment in this study while moving forward with clinical trials evaluating perifosine in combination with other novel agents, including bortezomib." Craig Henderson, MD, President of Keryx Biopharmaceuticals, commented, "We are excited with the KRX-0401 interim phase II clinical results in multiple myeloma. We are grateful to see top institutions in the field coming together led by Dr. Paul Richardson, to conduct this important clinical program for KRX-0401."

read more | 1588 reads

Gmail - Semafore Granted Nearly One Million Dollars to Study SF1126 in Multiple Myeloma Patients
By admin at 2006-12-08 01:52
 

 Semafore Pharmaceuticals, Inc. today announced receipt of a grant award from the Multiple Myeloma Research Foundation (MMRF) for a Phase l trial evaluating its Pl3K inhibitor SF1126 in multiple myeloma.

 

This is the second clinical trial grant awarded to Semafore-last week the company announced receipt of a grant from Cancer Treatment Research Foundation (CTRF) to help fund a Phase l trial of SF1126 in solid cancers.

 

Both Phase l trials are expected to commence in 2007. Separately, Semafore announced that multiple myeloma preclinical studies sponsored by the company and its collaborators at Emory University have been selected for an oral presentation at the upcoming 48th Annual Meeting of the American Society of Hematology (ASH.) "This generous grant from the MMRF will enable us to rapidly initiate a clinical trial of SF1126 in multiple myeloma," said Dr. Joseph Garlich, president and chief scientist of Semafore. "The MMRF has an outstanding track record of funding innovative research that has significantly increased the treatment options available to myeloma patients.

read more | 1692 reads

Familial (inherited) leukemia, lymphoma, and myeloma: an overview.
By admin at 2006-11-22 11:03
 

* Segel GB, * Lichtman MA. Department of Pediatrics, University of Rochester Medical Center, Rochester, NY 14642, USA.

 

We have reviewed the world's literature that addresses familial leukemiaterm, lymphomaterm, and myeloma. We have catalogued the phenotypic abnormalities associated with an increased risk of developing a hematological malignancy. These syndromes, such as Fanconi anemia or familial platelet syndrome, have been well characterized and in many cases the gene responsible for the predisposition has been defined. We have focused, however, on reports of a familial incidence of hematological malignancy in which no prior predisposing syndrome was reported. In this circumstance, so-called pure familial leukemia, lymphoma, or myeloma, the intergenerational incidence of disease occurred in ostensibly healthy persons. These families have been grouped into sets in which (a) anticipation, (b) immune abnormalities, (c) linkage to HLA phenotypes, (d) linkage to chromosome abnormalities, or (e) gene abnormalities have been reported.

read more | 3077 reads

Multiple Myeloma
By admin at 2006-11-21 05:35

Most patients with multiple myeloma develop symptoms of the condition over a period of a few weeks or months. Some (less than 10 per cent) may have already been found to have an abnormal protein (paraprotein) in their blood, perhaps by chance through routine investigation and are therefore under medical supervision.

 

They might then develop an alteration in their condition, such as a bone lesion, and then need to begin therapy.

 

Not everyone with an abnormal paraprotein has myeloma and not everyone with myeloma requires treatment. Once treatment is commenced, patients are followed up regularly and monitored carefully. More than 75 per cent of patients will respond to therapy, and the level of the abnormal protein will fall. In less than a third of patients the paraprotein disappears completely (typically in response to more intensive therapy), thus the patient achieves a 'complete remission'. A characteristic feature of multiple myeloma is that the disease enters a stable, or 'plateau' phase - during which time the patient is well, requires no treatment, and measurable disease indicators are stable. This phase typically lasts 12 to 40 months but it can be 10 to 15 years or more. Unfortunately, some patients deteriorate before ever reaching a stable phase.

read more | 10235 reads

Syndicate content
 
Search

sponsored links




Donate


Newsletter



Subscribe to our newsletter to receive info on our site or upcoming clinical trials
Email

Confirm your email address

HTML format
State

Please select the newsletters you want to sign up to:

  • Cancerfocus
    Receive updates from Cancerfocus.
  • Breast
  • Colon
  • Kidney
  • Leukemia
  • Liver
  • Lung
  • Melanoma
  • Mesothelioma
  • Myeloma
  • Neck
  • Pancreatic
  • Prostate




Syndicate
Syndicate content


All times are GMT -5. The time now is 05:01 PM.